StoneWise, a Chinese pharmaceutical firm that uses AI to accelerate the development of new drugs, has received an aggregate of $100 million in its Series B and B+ rounds of financing, it announced on Monday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
